Marina I. Smirnova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marina I. Smirnova has a total of 255 co-authors. Here are the top co-authors by number of shared publications:
- Oksana Mikhailovna Drapkina
National Medical Research Center for Therapy and Preventive Medicine, Ministry of Health of Russia
25 shared publications - Ruslan Nikolaevich Shepel
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
13 shared publications - Vladimir M. Gorbunov
National Medical Research Center for Therapy and Preventive Medicine
13 shared publications - Anna M. Kalinina
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
11 shared publications - Sergey Nikolaevich Avdeev
Sechenov First Moscow State Medical University, Moscow, Russia
11 shared publications - L. Yu. Drozdova
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
10 shared publications
Latest Publications
- 14 October 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (9)
Serum Parkin protein level is a potential differential diagnostic marker for asthma and chronic obstructive pulmonary disease
In clinical practice, the differential diagnosis of asthma and chronic obstructive pulmonary disease (COPD) remains challenging. Differences in the serum proteomic profiles of patients with asthma and COPD may serve as a basis for identifying disease-specific markers. Objective. To evaluate the diagnostic potential of serum Parkin protein for differentiating between asthma and chronic obstructive pulmonary disease using research databases of patients with chronic respiratory diseases and the Biobank of the National Medical Research Center for Therapy and Preventive Medicine. Materials and methods. A comparative prospective study included outpatients with asthma (n=76) and COPD (n=68) outside of exacerbation, patients without chronic respiratory diseases (control; n=43); mean age 59±11 years, 52% men. The level of Parkin in blood serum was determined by an in-house ELISA using anti-Parkin primary antibodies and conjugated secondary antibodies, while the levels of immunoglobulin E, eosinophil cationic protein, alpha-1-antitrypsin, C-reactive protein, fibrinogen, lipopolysaccharide, and trimethylamine N-oxide were measured by means of commercial ready-to-use ELISA kits. Statistical analysis was performed using the SPSS software package (v. 23). Results. Parkin protein levels in patients with asthma were lower than in patients with COPD or control subjects (p<0.05; asthma vs. COPD: rho=0.200, p=0.016; asthma vs. control: rho=0.262, p=0.004), correlated with lymphocyte levels (r=0.352, p=0.004), and were not associated with asthma exacerbations. The ability to differentiate asthma from COPD using Parkin protein levels was confirmed by ROC analysis (AUC=0.35±0.04, p=0.002). Logistic regression analysis revealed an association between Parkin protein levels and asthma, adjusted for sex and age (B = –0.174; p=0.009). In the asthma group, the use of maintenance medications was not associated with Parkin protein levels; however, when the three groups were combined, the use of inhaled glucocorticoids correlated with these levels (rho= –0.171; p=0.019). Conclusion. The signaling pathway associated with the regulation of Parkin protein is involved in the pathogenesis of asthma. Presumably, the reduced level of Parkin in asthma (compared to chronic obstructive pulmonary disease and the absence of chronic respiratory diseases) is associated with impaired mitophagy — a critically important mechanism underlying asthma. Assessing the level of this protein in blood serum holds significant promise for the differential diagnosis of asthma, chronic obstructive pulmonary disease, and chronic respiratory symptoms.
- 14 October 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (9)
Serum Parkin protein level is a potential differential diagnostic marker for asthma and chronic obstructive pulmonary disease
In clinical practice, the differential diagnosis of asthma and chronic obstructive pulmonary disease (COPD) remains challenging. Differences in the serum proteomic profiles of patients with asthma and COPD may serve as a basis for identifying disease-specific markers. Objective. To evaluate the diagnostic potential of serum Parkin protein for differentiating between asthma and chronic obstructive pulmonary disease using research databases of patients with chronic respiratory diseases and the Biobank of the National Medical Research Center for Therapy and Preventive Medicine. Materials and methods. A comparative prospective study included outpatients with asthma (n=76) and COPD (n=68) outside of exacerbation, patients without chronic respiratory diseases (control; n=43); mean age 59±11 years, 52% men. The level of Parkin in blood serum was determined by an in-house ELISA using anti-Parkin primary antibodies and conjugated secondary antibodies, while the levels of immunoglobulin E, eosinophil cationic protein, alpha-1-antitrypsin, C-reactive protein, fibrinogen, lipopolysaccharide, and trimethylamine N-oxide were measured by means of commercial ready-to-use ELISA kits. Statistical analysis was performed using the SPSS software package (v. 23). Results. Parkin protein levels in patients with asthma were lower than in patients with COPD or control subjects (p<0.05; asthma vs. COPD: rho=0.200, p=0.016; asthma vs. control: rho=0.262, p=0.004), correlated with lymphocyte levels (r=0.352, p=0.004), and were not associated with asthma exacerbations. The ability to differentiate asthma from COPD using Parkin protein levels was confirmed by ROC analysis (AUC=0.35±0.04, p=0.002). Logistic regression analysis revealed an association between Parkin protein levels and asthma, adjusted for sex and age (B = –0.174; p=0.009). In the asthma group, the use of maintenance medications was not associated with Parkin protein levels; however, when the three groups were combined, the use of inhaled glucocorticoids correlated with these levels (rho= –0.171; p=0.019). Conclusion. The signaling pathway associated with the regulation of Parkin protein is involved in the pathogenesis of asthma. Presumably, the reduced level of Parkin in asthma (compared to chronic obstructive pulmonary disease and the absence of chronic respiratory diseases) is associated with impaired mitophagy — a critically important mechanism underlying asthma. Assessing the level of this protein in blood serum holds significant promise for the differential diagnosis of asthma, chronic obstructive pulmonary disease, and chronic respiratory symptoms.
- Open Access
- 16 July 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2S) , 59-88
Follow-up monitoring of patients with carotid artery occlusion and stenosis by a primary care physician. Guidelines
Atherosclerosis of the extracranial carotid artery is one of the main causes of cerebrovascular accidents. Considering the high medical and social significance of the consequences of cerebrovascular accidents, in particular ischemic stroke, and the relevance of an interdisciplinary approach to the optimal management of patients with carotid artery atherosclerosis, these guidelines describes the management of patients with carotid artery occlusion and stenosis by a primary care physician. These guidelines allow the practitioner to make informed clinical decisions when conducting clinical observation. The guidelines are, first of all, intended for primary care physicians, general practitioners, as well as for nurses working with these doctors, for paramedics at primary care facilities performing the doctor functions within follow-up monitoring. These guidelines should be of no less interest to public health physicians, heads of primary care facilities and their departments.
- 16 July 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2S) , 59-88
Open AccessFollow-up monitoring of patients with carotid artery occlusion and stenosis by a primary care physician. Guidelines
Atherosclerosis of the extracranial carotid artery is one of the main causes of cerebrovascular accidents. Considering the high medical and social significance of the consequences of cerebrovascular accidents, in particular ischemic stroke, and the relevance of an interdisciplinary approach to the optimal management of patients with carotid artery atherosclerosis, these guidelines describes the management of patients with carotid artery occlusion and stenosis by a primary care physician. These guidelines allow the practitioner to make informed clinical decisions when conducting clinical observation. The guidelines are, first of all, intended for primary care physicians, general practitioners, as well as for nurses working with these doctors, for paramedics at primary care facilities performing the doctor functions within follow-up monitoring. These guidelines should be of no less interest to public health physicians, heads of primary care facilities and their departments.
- Open Access
- 16 July 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2S) , 89-130
Follow-up monitoring of patients with chronic kidney disease by primary care physicians. Guidelines
The high and steadily increasing prevalence of chronic kidney disease (CKD) is a significant medical and social problem. CKD complications significantly reduce quality of life and increase the risk of disability, hospitalization, and death. Timely identification and correction of modifiable risk factors for CKD progression underpins secondary prevention measures. These guidelines describe the management of follow-up monitoring for CKD patients by a general practitioner and incorporate modern approaches to diagnosing disease severity and complications (clinical and paraclinical methods), as well as disease treatment and complication prevention. Application of these guidelines will enable physicians to make informed clinical decisions based on the presented diagnostic algorithm (examinations, consultations). These guidelines are intended for general practitioners, family doctors, and for nursing staff working with these physicians, for paramedics performing the doctor functions of managing follow-up monitoring. These guidelines are also intended for healthcare executives, heads of primary care facilities, and their departments.
- 16 July 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2S) , 89-130
Open AccessFollow-up monitoring of patients with chronic kidney disease by primary care physicians. Guidelines
The high and steadily increasing prevalence of chronic kidney disease (CKD) is a significant medical and social problem. CKD complications significantly reduce quality of life and increase the risk of disability, hospitalization, and death. Timely identification and correction of modifiable risk factors for CKD progression underpins secondary prevention measures. These guidelines describe the management of follow-up monitoring for CKD patients by a general practitioner and incorporate modern approaches to diagnosing disease severity and complications (clinical and paraclinical methods), as well as disease treatment and complication prevention. Application of these guidelines will enable physicians to make informed clinical decisions based on the presented diagnostic algorithm (examinations, consultations). These guidelines are intended for general practitioners, family doctors, and for nursing staff working with these physicians, for paramedics performing the doctor functions of managing follow-up monitoring. These guidelines are also intended for healthcare executives, heads of primary care facilities, and their departments.
- Open Access
- 16 July 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2S) , 241-268
Follow-up of patients with interstitial lung diseases by a primary care physician. Guidelines
Interstitial lung diseases are a heterogeneous group of pathologies, the most common of which is idiopathic pulmonary fibrosis. The causes of interstitial diseases often remain unknown, but their pathogenesis is based on the gradual replacement of normal lung tissue with fibrous tissue. More than half of patients with interstitial lung diseases experience fibrosis progression, worsening symptoms, and the onset of respiratory failure within 2 years of diagnosis. Early diagnosis and timely follow-up are the primary means of disease management, particularly for idiopathic pulmonary fibrosis. This includes slowing disease progression, reducing the frequency and severity of exacerbations, and reducing the risk of developing and progressing different acute and chronic conditions that can affect respiratory symptoms and the prognosis of interstitial lung diseases. These guidelines are intended for primary care physicians, general practitioners, nurses working with these physicians, and paramedics at primary care facilities performing the doctor functions, including conducting outpatient follow-up. These guidelines are also intended for specialists such as pulmonologists, allergists/ immunologists, and other specialists involved in the care of patients with interstitial lung diseases. In addition, these guidelines are intended for heads of healthcare facilities (or its divisions) providing primary care, as well as students, residents, and postgraduate students at medical and pharmaceutical educational institutions.
- 16 July 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2S) , 241-268
Open AccessFollow-up of patients with interstitial lung diseases by a primary care physician. Guidelines
Interstitial lung diseases are a heterogeneous group of pathologies, the most common of which is idiopathic pulmonary fibrosis. The causes of interstitial diseases often remain unknown, but their pathogenesis is based on the gradual replacement of normal lung tissue with fibrous tissue. More than half of patients with interstitial lung diseases experience fibrosis progression, worsening symptoms, and the onset of respiratory failure within 2 years of diagnosis. Early diagnosis and timely follow-up are the primary means of disease management, particularly for idiopathic pulmonary fibrosis. This includes slowing disease progression, reducing the frequency and severity of exacerbations, and reducing the risk of developing and progressing different acute and chronic conditions that can affect respiratory symptoms and the prognosis of interstitial lung diseases. These guidelines are intended for primary care physicians, general practitioners, nurses working with these physicians, and paramedics at primary care facilities performing the doctor functions, including conducting outpatient follow-up. These guidelines are also intended for specialists such as pulmonologists, allergists/ immunologists, and other specialists involved in the care of patients with interstitial lung diseases. In addition, these guidelines are intended for heads of healthcare facilities (or its divisions) providing primary care, as well as students, residents, and postgraduate students at medical and pharmaceutical educational institutions.
- 8 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (6)
The effect of stabilized hydrogen inhalation on clinical and functional parameters in patients with chronic obstructive pulmonary disease
The specific course of chronic obstructive pulmonary disease necessitates the search for novel therapeutic approaches capable of influencing disease progression. Inhalations of stabilized hydrogen (H(H2O)m; H2) are considered as a promising but insufficiently studied direction. Objective. To evaluate the effect of a 10-day course of stabilized hydrogen inhalation on clinical and functional parameters in patients with chronic obstructive pulmonary disease in remission. Materials and methods. A randomized (1:1) blinded controlled study was performed with the inclusion of 24 outpatients (age 65.8±8.1 years; 75% men). Patients in the H+ group (n=13) received inhalations of H2 with water vapor, while patients in the H– group (n=11) — inhalations of only water vapor. The course consisted of 10 sessions (minimum 8) of 60 minutes each. Evaluation was done before, immediately after the course and in 28 days. Results. Patients in both groups showed a reduction in the severity of COPD symptoms (CAT test) and an improvement in quality of life. A lower level of pulmonary artery systolic pressure (p=0.033) and an increase in 6-minute walk distance were reported in patients of the H+ group. The impact of H2 on key markers of systemic inflammation (blood levels of leucocytes, C-reactive protein, fibrinogen, eosinophils), spirometry and electrocardiography indicators was not detected. The reported adverse events were mild in severity. Their incidence did not differ statistically between groups. Conclusion. Inhalations of stabilized H2 alleviate symptoms of chronic obstructive pulmonary disease and improve quality of life, providing statistically significant advantages in terms of pulmonary artery systolic pressure and increased exercise tolerance. The method has a favorable safety profile: there were no moderate or severe side effects.
- 8 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (6)
The effect of stabilized hydrogen inhalation on clinical and functional parameters in patients with chronic obstructive pulmonary disease
The specific course of chronic obstructive pulmonary disease necessitates the search for novel therapeutic approaches capable of influencing disease progression. Inhalations of stabilized hydrogen (H(H2O)m; H2) are considered as a promising but insufficiently studied direction. Objective. To evaluate the effect of a 10-day course of stabilized hydrogen inhalation on clinical and functional parameters in patients with chronic obstructive pulmonary disease in remission. Materials and methods. A randomized (1:1) blinded controlled study was performed with the inclusion of 24 outpatients (age 65.8±8.1 years; 75% men). Patients in the H+ group (n=13) received inhalations of H2 with water vapor, while patients in the H– group (n=11) — inhalations of only water vapor. The course consisted of 10 sessions (minimum 8) of 60 minutes each. Evaluation was done before, immediately after the course and in 28 days. Results. Patients in both groups showed a reduction in the severity of COPD symptoms (CAT test) and an improvement in quality of life. A lower level of pulmonary artery systolic pressure (p=0.033) and an increase in 6-minute walk distance were reported in patients of the H+ group. The impact of H2 on key markers of systemic inflammation (blood levels of leucocytes, C-reactive protein, fibrinogen, eosinophils), spirometry and electrocardiography indicators was not detected. The reported adverse events were mild in severity. Their incidence did not differ statistically between groups. Conclusion. Inhalations of stabilized H2 alleviate symptoms of chronic obstructive pulmonary disease and improve quality of life, providing statistically significant advantages in terms of pulmonary artery systolic pressure and increased exercise tolerance. The method has a favorable safety profile: there were no moderate or severe side effects.
- 20 May 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2) , 47-73
Follow-up of pa tients with pneumonia by a primary care physician. Guidelines
- 20 May 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2) , 47-73
Follow-up of pa tients with pneumonia by a primary care physician. Guidelines
- 22 April 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (4) , 83-90
The results of stabilised hydrogen inhalations in patients with asthma
Objective. To evaluate the effect of stabilized hydrogen (H(H2O)m; H) inhalations on the clinical and functional characteristics of patients with uncontrolled and partially controlled asthma. Materials and methods. A double-blind, controlled study was conducted involving 25 outpatients with asthma (age 57.8±11.2 years, 72% females), matched for age, sex, and therapy. The patients were randomized 2:1 in the following groups: H+ (n=17) and H– (n=8). Patients in the H+ group received inhalations with an aerosol mixture of water steam and H for 60 min per day; patients in the H– group received only water steam inhalations. The number of inhalations was 10 (minimum 8), with intervals of no more than 2 days. Patients were examined at baseline, immediately after the treatment, and 28 days later. Results. In both groups of patients, asthma symptoms improved (ACT test), and 6-minute walk distance increased. In patients in the H+ group, exercise tolerance improved (mMRC and Borg scales, p0.05), including in the main spirometry, electrocardiography, echocardiography, and systemic inflammation parameters. The adverse events were mild, including a transient decrease in O2 saturation during inhalation; their incidence did not differ between the groups. Conclusion. In a small randomized controlled trial, stabilized hydrogen inhalation therapy improved asthma control and exercise tolerance, outcomes similar to those with water steam inhalation; no moderate or severe adverse events were reported.
- 22 April 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (4) , 83-90
The results of stabilised hydrogen inhalations in patients with asthma
Objective. To evaluate the effect of stabilized hydrogen (H(H2O)m; H) inhalations on the clinical and functional characteristics of patients with uncontrolled and partially controlled asthma. Materials and methods. A double-blind, controlled study was conducted involving 25 outpatients with asthma (age 57.8±11.2 years, 72% females), matched for age, sex, and therapy. The patients were randomized 2:1 in the following groups: H+ (n=17) and H– (n=8). Patients in the H+ group received inhalations with an aerosol mixture of water steam and H for 60 min per day; patients in the H– group received only water steam inhalations. The number of inhalations was 10 (minimum 8), with intervals of no more than 2 days. Patients were examined at baseline, immediately after the treatment, and 28 days later. Results. In both groups of patients, asthma symptoms improved (ACT test), and 6-minute walk distance increased. In patients in the H+ group, exercise tolerance improved (mMRC and Borg scales, p0.05), including in the main spirometry, electrocardiography, echocardiography, and systemic inflammation parameters. The adverse events were mild, including a transient decrease in O2 saturation during inhalation; their incidence did not differ between the groups. Conclusion. In a small randomized controlled trial, stabilized hydrogen inhalation therapy improved asthma control and exercise tolerance, outcomes similar to those with water steam inhalation; no moderate or severe adverse events were reported.
- Open Access
- 14 March 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (2) , 4769
Outpatient monitoring of patients with stable coronary artery disease by a primary care physician. Guidelines
These guidelines describe the management of outpatient monitoring of patients with stable coronary artery disease by a general practitioner and include modern approaches to diagnosis — clinical and paraclinical methods — as well as treatment and prevention of complications. These guidelines will enable physicians to make informed clinical decisions within outpatient monitoring for patients with stable coronary artery disease based on the related algorithm presented (examinations, consultations). The guidelines are intended for general practitioners, family doctors, as well as for mid-level health providers working with the above-mentioned doctors, for paramedics performing the doctor functions regarding organizing and conducting outpatient follow-up. These guidelines can be used by healthcare executives, heads of primary care facilities, and their departments.
- 14 March 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (2) , 4769
Open AccessOutpatient monitoring of patients with stable coronary artery disease by a primary care physician. Guidelines
These guidelines describe the management of outpatient monitoring of patients with stable coronary artery disease by a general practitioner and include modern approaches to diagnosis — clinical and paraclinical methods — as well as treatment and prevention of complications. These guidelines will enable physicians to make informed clinical decisions within outpatient monitoring for patients with stable coronary artery disease based on the related algorithm presented (examinations, consultations). The guidelines are intended for general practitioners, family doctors, as well as for mid-level health providers working with the above-mentioned doctors, for paramedics performing the doctor functions regarding organizing and conducting outpatient follow-up. These guidelines can be used by healthcare executives, heads of primary care facilities, and their departments.
- Open Access
- 9 February 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (1S) , 93-117
“School” for patients with asthma. Guidelines
Школа для больных с бронхиальной астмой. Методические рекомендации
- 9 February 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (1S) , 93-117
Open Access“School” for patients with asthma. Guidelines
Школа для больных с бронхиальной астмой. Методические рекомендации
- Open Access
- 9 February 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (1S) , 118-135
"School" for patients with chronic obstructive pulmonary disease. Guidelines
Школа для больных с хронической обструктивной болезнью легких. Методические рекомендации
- 9 February 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (1S) , 118-135
Open Access"School" for patients with chronic obstructive pulmonary disease. Guidelines
Школа для больных с хронической обструктивной болезнью легких. Методические рекомендации